Medicinal mushroom supplement
Reishi Mushroom
In a crossover study of 12 healthy men, ganoderic acid A from a reishi water extract had a half-life of 0.66 hours, against the app's 8 hours for reishi.1
Reishi Mushroom after one dose: 50% at ~8 h, 25% at 16 h, 12.5% at 24 h.
Drawn from the half-life in the app's model, ~8 h. The model's figures
- Compound
- Reishi Mushroom
- Symbol
- REI
- Family
- Supplements
- Parts
- 13
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Reishi is the common name of Ganoderma lucidum, which Klupp and colleagues describe as "a traditional Chinese medicinal mushroom also called Ling Zhi or Reishi".2 The app lists it as a medicinal mushroom supplement taken by mouth, grades its evidence as emerging, and gives a typical dose of 1 to 3 g/day.
The Gulf War illness trial used a hot water and alcohol extract with 12% polysaccharides and 4% triterpene, the pharmacokinetic study used a water extract of fruiting bodies, the metabolic syndrome trial used a 10:1 extract plus spores, and the neurasthenia trial used a polysaccharide extract (Ganopoly).3,1,2,4 Younger and colleagues note that "products can vary significantly in purity, ratios of active components, presence of added compounds to enhance effects, quality of packaging, and many other factors".3
A DailyMed search for "reishi" returned 8 labels, all multi-ingredient products such as homeopathic pellets, a skin serum powder and capsule blends; no single-ingredient reishi label was identified.
How it works
Sources in this part
The app's notes describe reishi as a calming adaptogen whose active profile comes from triterpenes and beta-glucans. The study texts saved for this compound do not use the word "adaptogen" or "calming" for reishi. Younger and colleagues state in their introduction that reishi "contains several triterpenoids and polysaccharides with demonstrated anti-inflammatory properties", citing laboratory and animal work rather than their own measurements.3 The same authors add that "some reishi extracts have immunostimulating properties", and that "it is unclear how the whole mushroom will affect conditions of purported inflammatory origins".3 Klupp and colleagues note that "in vitro and diabetic rodent studies suggest that Ganoderma lucidum can improve blood glucose and serum insulin levels", and their own randomised trial in people, described below, reported no effect on blood glucose.2
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~8 h
- Bioavailability
- 40%
- Typical dose
- 1–3 g/day
- Route
- Oral
- Time to peak
- ~3 h
Sources in this part
The human pharmacokinetic study among the sources used here measured ganoderic acid A, one triterpenoid in the extract, after a single oral dose of a reishi water extract.1
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~8 h | Ganoderic acid A elimination half-life 0.66 ± 0.33 h after a single 3,000 mg water extract in healthy Thai men, fasted; the same group's earlier study gave 0.62 ± 0.17 h1 |
| Time to peak | ~3 h | Ganoderic acid A time to peak concentration 0.54 ± 0.10 h in the same study1 |
| Bioavailability | 40% | No percentage given; an earlier study of ganoderic acid A is described as showing "relatively low oral bioavailability and rapid elimination"1 |
| Peak concentration | Not listed in the app | Ganoderic acid A Cmax 2.24 ± 1.31 ng/mL after 3,000 mg alone1 |
The app's figures of about 8 hours and about 3 hours are for reishi as a whole, whereas the source figures of 0.66 hours and 0.54 hours are for ganoderic acid A alone. No half-life or time to peak for the beta-glucan fraction or for the whole preparation was reported in that study.1
Deeper analysis: the ganoderic acid A pharmacokinetic study
Tawasri and colleagues, at Chiang Mai University, Thailand, reported the study in BioMed Research International in 2016.1 Its design was "a randomized, open-label, single-dose, two-phase crossover study with a washout period of at least two weeks".1 The question was whether 2,500 mg of ascorbic acid changes ganoderic acid A levels; the figures above come from the reishi-alone phase.1 The authors enrolled "12 healthy Thai males aged 18–40 years and with a body mass index (BMI) of 18.5 to 24.9 kg/m2", gave them 3,000 mg of the extract after an overnight fast, and took blood samples up to 8 hours.1 Ascorbic acid did not significantly alter Cmax (2.39 ± 0.99 against 2.24 ± 1.31 ng/mL), time to peak (0.44 ± 0.19 against 0.54 ± 0.10 h), AUC or half-life (0.66 ± 0.30 against 0.66 ± 0.33 h).1 One participant had levels below the limit of quantitation at every time point except 0.75 hours, so 11 rather than 12 participants entered the half-life and AUC comparisons.1 The authors report that all 12 participants "completed the study protocol without any adverse events".1 Among their limitations, they note that "in practice plasma concentrations in all subjects were quantifiable for a maximum of two hours after dosing", because the assay's lower limit of quantitation was 0.50 ng/mL.1 The authors acknowledge "the financial support provided by the Thai Traditional Medical Knowledge Fund, Department for Development of the Thai Traditional and Alternative Medicine, Ministry of Public Health, Thailand, and by the Faculty of Medicine, Chiang Mai University, Thailand", and declare "There are no competing interests."1
Human studies
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Klupp and colleagues, Scientific Reports 20162 | Double-blind, randomised, placebo-controlled; reishi, reishi with Cordyceps sinensis, or placebo, with the two active arms pooled for analysis2 | 84 adults with type 2 diabetes mellitus and metabolic syndrome2 | 3 g/day of Ganoderma lucidum, with or without Cordyceps sinensis, for 16 weeks2 | HbA1c difference 0.13% (95% CI -0.35 to 0.60, p = 0.60) and fasting plasma glucose 0.03 mmol/L (95% CI -0.90 to 0.96, p = 0.95); no effect on any secondary outcome2 |
| Klupp and colleagues, Cochrane Database of Systematic Reviews 20155 | Systematic review and meta-analysis of randomised and controlled clinical trials5 | Five trials with a total of 398 participants; the three trials with usable data all had type 2 diabetes5 | 1.4 g to 3 g per day against placebo for 12 to 16 weeks5 | HbA1c weighted mean difference -0.10% (95% CI -1.05% to 0.85%; 130 participants); adverse events 1.67 times more likely (RR 1.67, 95% CI 0.86 to 3.24), described as not a statistically significantly greater risk and not serious side effects5 |
| Wicks and colleagues, American Journal of Chinese Medicine 20076 | Double-blind, randomised, placebo-controlled safety trial6 | 16 healthy volunteers6 | 2 grams of the extract or placebo twice daily for 10 consecutive days6 | No adverse effects observed against placebo; a CD56 cell count increase did not reach statistical significance6 |
| Kwok and colleagues, Anesthesia and Analgesia 20057 | Prospective, randomised, double-blind, placebo-controlled7 | 40 healthy volunteers (20 per group)7 | Capsules, 1.5 g daily for 4 weeks, with testing at 4 and 8 weeks7 | No significant between-group differences in coagulation, fibrinogen, platelet function or thrombelastography; all values within the normal range7 |
| Tang and colleagues, Journal of Medicinal Food 20054 | Randomised, double-blind, placebo-controlled, parallel, multicentre4 | 132 patients with neurasthenia, 123 assessable4 | Polysaccharide extract (Ganopoly), 1,800 mg three times a day for 8 weeks4 | CGI severity score and sense of fatigue fell 15.5% and 28.3% from baseline against 4.9% and 20.1% on placebo; sense of well-being score at day 56 rose 38.7% from baseline against 29.7% on placebo; 51.6% (32 of 62) against 24.6% (15 of 61) rated more than minimally improved (P = .002); Ganopoly was described as well tolerated4 |
| Noguchi and colleagues, Asian Journal of Andrology 20088 | Double-blind, placebo-controlled, randomised, dose-ranging8 | Men with lower urinary tract symptoms; 12 on placebo, 12, 12 and 14 on the three doses8 | Extract 0.6 mg, 6 mg or 60 mg once daily8 | Statistical significances in the magnitude of changes between the experimental groups at weeks 4 and 8 (the source does not say which groups); no changes in peak urine flow rate, residual urine, prostate volume or PSA; overall administration well tolerated, with no major adverse effects8 |
| Younger and colleagues, International Journal of Environmental Research and Public Health 20213 | Placebo-controlled, pseudo-randomised crossover screening trial3 | Men with Gulf War illness; 10 completed the reishi protocol (29 men received at least one of the three botanicals in the report, five were assigned two, and data from four were excluded)3 | 1600 mg/day, then 3200 mg/day, each for 30 days after 30 days of placebo3 | Symptom severity unchanged from placebo at the lower dose (p = 0.603) and higher at the higher dose (p = 0.012); pain and fatigue not different from placebo3 |
| Jin and colleagues, Cochrane Database of Systematic Reviews 20169 | Systematic review and meta-analysis of randomised trials in cancer9 | Five randomised trials in patients with pathology-diagnosed cancer9 | Ganoderma lucidum medications against active or placebo control9 | Tumour response, pooled from two studies, RR 1.50 (95% CI 0.90 to 2.51), reported in the results text as statistically insignificant with P = 0.12 (the summary section gives P = 0.02); no trial recorded long-term survival; quality of primary studies "generally unsatisfying"9 |
| Xuanwu Hospital, Beijing, NCT00224263 (registry entry)10 | Phase 2, randomised, double-blind, placebo-controlled, dose-finding10 | 360 planned, people with early Parkinson's disease on stable L-dopa10 | Two dosage groups and placebo; treatment one year10 | Status completed; the entry as retrieved does not report results10 |
Deeper analysis: the metabolic syndrome trial (Klupp, 2016)
Klupp and colleagues, from the National Institute of Complementary Medicine at Western Sydney University, reported the trial in Scientific Reports in 2016.2 Its design was "multiple-blinded, randomised, placebo-controlled, parallel design", registered with the Australian New Zealand Clinical Trials Registry as ACTRN12606000485538.2 Participants had a diagnosis of type 2 diabetes mellitus and at least two other metabolic syndrome criteria, and all took eight capsules a day for 16 weeks.2 The reishi capsules held 2,240 mg of a 10:1 extract and 740 mg of spores a day.2 The primary outcomes were HbA1c and fasting plasma glucose, with blood pressure, lipids, waist circumference, BMI, quality of life and C-reactive protein among the secondary outcomes.2 Of those screened in person, 84 met the inclusion criteria, and "Nine persons withdrew from the clinical trial".2 Because recruitment fell short, the two reishi arms were pooled into a combined group of 54 against 30 on placebo.2 The authors call any changes in secondary outcome measures negligible: "mean arterial blood pressure decreased by 0.3 mmHg, triglycerides by 0.1 mmol/L, C-reactive protein by 0.7 mg/L, and HDL and BMI did not change".2 Participants in the reishi, reishi with Cordyceps, and placebo groups "each reported 52, 35, and 43 adverse events, respectively", and the two serious events, a stroke and a breast cancer diagnosis, "were not considered attributable to the trial intervention".2 The authors state that "The primary limitation of this clinical trial was the sample size", and that at completion "the sample size was 50% of that specified in the protocol".2 They add that the safety variables were evaluated descriptively because the study was underpowered for inferential testing.2 They also report that recruitment was slow, that the trial period was extended by 18 months, and that the inclusion criteria were amended to allow enrolment of persons with non-alcoholic fatty liver syndrome.2 On funding, the article says that "Organisations who contributed funds to this collaborative trial are Allife Australia Pty Ltd, Western Sydney University, Cardiac Health Institute, and Sydney Adventist Hospital", and that the research "was sponsored by Allife International Pty Ltd under a contract that denied them involvement in conducting the study, and analysing and reporting results".2 It adds that Allife Australia provided "in-kind trial medications and financial funding".2 The authors assessed their own trial as at "low risk of bias", and conclude that "There was no statistically significant or clinically significant effect of Ganoderma lucidum on hyperglycaemia, hypertension, or lipid profile in adults with metabolic syndrome or type 2 diabetes mellitus."2
Deeper analysis: the Gulf War illness screening trial (Younger, 2021)
Younger and colleagues, at the University of Alabama at Birmingham, reported the trial in the International Journal of Environmental Research and Public Health in 2021.3 The trial was part of a larger screening of nine botanicals, with the stated goal "to rapidly identify agents to prioritize for further efficacy research".3 Participants were men aged 44 to 65 who met the Kansas Gulf War illness case criteria; each botanical was taken for 30 days of placebo, 30 days of lower dose and 30 days of higher dose, in that fixed order.3 For the ten people who completed the reishi protocol, severity was 34.1 at baseline, 35.0 on placebo, 35.2 on lower-dose reishi and 38.5 on higher-dose reishi.3 Severity was higher in every condition than at baseline, including placebo, and the higher dose differed from placebo (p = 0.012) and from the lower dose (p = 0.046).3 The authors call the reishi finding "unexpected", and write that "Given the atypical placebo effect, we are hesitant to conclude that reishi can exacerbate GWI symptoms, but it must be considered".3 Individuals taking any antihypertensive medication were not allowed to take reishi in the trial, and the authors say the small sample "precludes statistical evaluation of adverse side-effects".3 Other stated limitations are that only men were included, "The item used as the primary outcome has not been validated", and that "the effect of dosage cannot be separated from the effect of treatment duration" because the lower dose always came first.3 The study was funded by Department of Defense Congressionally Directed Medical Research Programs grants and the National Center for Advancing Translational Sciences, the funding bodies "were not involved in the design of the study, collection and analysis of data, or manuscript preparation", and the authors "declare no conflict of interest".3
Deeper analysis: the two Cochrane reviews (Klupp, 2015; Jin, 2016)
The cardiovascular review by Klupp and colleagues searched databases to 2014 and judged risk of bias "low for one study and unclear for the remaining four" of the five included trials.5 Its authors conclude that the evidence "does not support the use of G lucidum for treatment of cardiovascular risk factors in people with type 2 diabetes mellitus".5 The review lists support from the National Institute of Complementary Medicine, Australia and the Cardiac Health Institute, Australia, and states that five of its seven authors were authors of an included trial.5 The cancer review by Jin and colleagues reports a pooled risk ratio for tumour response of 1.50 (95% CI 0.90 to 2.51) from two studies, which its results text calls statistically insignificant (P = 0.12) and its summary section gives as P = 0.02, and that CD3, CD4 and CD8 percentages rose in pooled immune data.9 It also states that "G. lucidum treatment alone did not demonstrate the same regression rate as that seen in combined therapy" and that "The methodological quality of primary studies was generally unsatisfying and the results were reported inadequately in many aspects".9 Its authors write that the review "did not find sufficient evidence to justify the use of G. lucidum as a first-line treatment for cancer", and report that "None of the authors is involved in clinical trials or have direct financial interest in the subject matter of this review."9
Doses reported in studies and on labels
No single-ingredient reishi label was identified in DailyMed, so the table lists only doses reported in studies, each with its reference. The typical dose in the app is 1 to 3 g/day.
| Source | Preparation and route | Dose reported | People and length |
|---|---|---|---|
| Klupp 20162 | Capsules of 10:1 extract plus spores, oral | 3 g/day of Ganoderma lucidum, four capsules morning and four at night | 84 adults with type 2 diabetes and metabolic syndrome, 16 weeks |
| Kwok 20057 | Capsules, oral | 1.5 g daily | 20 healthy volunteers on reishi and 20 on placebo, 4 weeks |
| Wicks 20076 | Extract, oral | 2 grams twice daily | 16 healthy volunteers, 10 consecutive days |
| Younger 20213 | Hot water and alcohol extract, 12% polysaccharides and 4% triterpene, oral capsules | 1600 mg/day and 3200 mg/day, split between morning and evening | Men with Gulf War illness, 30 days at each dose after 30 days of placebo |
| Tang 20054 | Polysaccharide extract (Ganopoly), oral | 1,800 mg three times a day | 132 patients with neurasthenia, 8 weeks |
| Noguchi 20088 | Extract, oral | 0.6 mg, 6 mg or 60 mg once daily | Men with lower urinary tract symptoms, 12 to 14 per group |
| Tawasri 20161 | Water extract dissolved in 200 mL of warm water, oral | One dose of 3,000 mg | 12 healthy Thai men, single dose, fasted |
Klupp and colleagues state that "There are no scientific data on a safe and effective dosage of Ganoderma lucidum."2
Side effects reported
In the 10-day safety trial of 16 healthy volunteers, Wicks and colleagues report that "no adverse effects were observed after the extract intake" compared with placebo, and describe the sample as small.6 In the 16-week metabolic syndrome trial, the reishi arms reported 52 and 35 adverse events and placebo 43, with two serious events not judged attributable to the intervention.2 The 2015 Cochrane review pooled one analysis in which adverse events were 1.67 times more likely on reishi (95% CI 0.86 to 3.24), described as not a statistically significantly greater risk and not serious side effects, and its summary says one study showed "some increased risk of mild harms" in the form of "nausea, diarrhoea or constipation".5 The same review says there "was not enough information to determine the overall safety of taking G lucidum".5 The cancer review reports that one study recorded three episodes of toxicity on reishi, "Two experienced nausea and one had insomnia", with "No patients developed hepatitis or abnormal liver function tests".9 In the Gulf War illness trial, the authors report that "Diarrhea was reported for each of the tested compounds and was the most likely event to be reported in the placebo condition".3 Across the 25 participants analysed for the three botanicals, one self-withdrew and one was investigator-withdrawn due to adverse events, and the authors say the small sample precludes statistical evaluation of adverse side-effects.3
Liver case reports
Two case reports describe liver injury after reishi products. Yuen and colleagues, in the Journal of Hepatology in 2004, published a letter titled "Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi)".12 Wanmuang and colleagues, in the Journal of the Medical Association of Thailand in 2007, describe "a case of fatal fulminant hepatitis associated with such a preparation".11 They write that "Both patients had taken other therapeutic agents and traditionally boiled Lingzhi without any toxic effect", and that the hepatotoxic episode occurred after "switching to taking Lingzhi in powder form for 1-2 months".11 They conclude that "The toxic role of Lingzhi powder needs close monitoring in the future, especially in combination with other drugs".11 Klupp and colleagues refer to one report of hepatotoxicity after 1 month of supplementation, which "was thought to be due to the excipient ingredients".2
Bloodwork and markers
Sources in this part
The app lists no markers to monitor for reishi. The trials above measured the following markers. Kwok and colleagues measured coagulation tests, fibrinogen, von Willebrand ristocetin cofactor activity, PFA-100 platelet function and thrombelastography in 40 healthy volunteers, and reported all values within the normal range after 4 weeks of 1.5 g daily.7 Klupp and colleagues report that pathology biochemistry panels "were found to be similar between intervention and control groups", and Younger and colleagues ran renal and hepatic panels before the higher dose.2,3
Regulatory and anti-doping status
Sources in this part
No entry naming reishi, Ganoderma or a mushroom was identified in the text retrieved of the World Anti-Doping Agency Prohibited List 2026. No single-ingredient reishi drug label was identified in DailyMed. The regulatory status of reishi as a food or supplement in the United States, European Union or Australia was not established from the sources used here. Klupp and colleagues state that reishi and Cordyceps sinensis "are listed as the safest drug class (Class 1 Drug) in the American Herbal Products Association Botanical Safety Handbook, with no known herb-drug interactions", an industry handbook, not a regulator.2
What is not known
Sources in this part
The studies identified give a half-life only for ganoderic acid A, not for the beta-glucans or the whole preparation, and no bioavailability percentage.1 The ganoderic acid A study measured one dose in 12 healthy men, quantifiable for a maximum of two hours, so a terminal half-life over several hours is not described by it.1 The trials described here used different preparations; the saved study texts do not use the term "dual-extract", and no comparison of extraction methods is described among the trials above, so no result is given here for the app's note that dual-extract products give a "full active profile". Results in people with type 2 diabetes, in Gulf War illness and in cancer patients receiving chemotherapy do not describe healthy people or other conditions.2,3,9 The Gulf War illness trial reported a higher symptom score on reishi but its authors were "hesitant" to conclude harm because of an unusual placebo response, so that direction is unresolved.3
Frequently asked questions
What is the half-life of reishi mushroom?
How long does reishi take to reach its peak level?
The app lists about 3 hours, while the same study reported a ganoderic acid A time to peak of 0.54 ± 0.10 hours.1
What is the bioavailability of reishi?
Is reishi banned by WADA?
No entry naming reishi, Ganoderma or a mushroom was identified in the text retrieved of the WADA Prohibited List 2026.
Did reishi lower blood sugar in trials?
In a 16-week trial of 84 adults with type 2 diabetes and metabolic syndrome, reishi at 3 g/day produced an HbA1c difference of 0.13% (95% CI -0.35 to 0.60, p = 0.60) against placebo.2 The 2015 Cochrane review likewise reported a weighted mean difference in HbA1c of -0.10% (95% CI -1.05% to 0.85%; 130 participants).5
Has reishi been linked to liver injury?
Two case reports describe hepatotoxicity after reishi powder or a reishi formulation, one of them fatal fulminant hepatitis.11,12 Wanmuang and colleagues write that both patients had taken other therapeutic agents.11 In the cancer review, no patient in the one study that reported toxicity developed hepatitis or abnormal liver function tests.9
Guides, tools and comparisons
References
- Tawasri P, et al. Effect of Oral Coadministration of Ascorbic Acid with Ling Zhi Preparation on Pharmacokinetics of Ganoderic Acid A in Healthy Male Subjects: A Randomized Crossover Study. BioMed Res Int 2016. PMC5055913
- Klupp NL, et al. A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome. Sci Rep 2016. PMC4980683
- Younger J, et al. A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Reishi Mushroom (Ganoderma lucidum), Stinging Nettle (Urtica dioica), and Epimedium (Epimedium sagittatum). Int J Environ Res Public Health 2021. PMC8037868
- Tang W, et al. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. J Med Food 2005. PMID 15857210
- Klupp NL, et al. Ganoderma lucidum mushroom for the treatment of cardiovascular risk factors. Cochrane Database Syst Rev 2015. PMC6486141
- Wicks SM, et al. Safety and tolerability of Ganoderma lucidum in healthy subjects: a double-blind randomized placebo-controlled trial. Am J Chin Med 2007. PMID 17597499
- Kwok Y, et al. A prospective, randomized, double-blind, placebo-controlled study of the platelet and global hemostatic effects of Ganoderma lucidum (Ling-Zhi) in healthy volunteers. Anesth Analg 2005. PMID 16037156
- Noguchi M, et al. Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: a double-blind, placebo-controlled randomized and dose-ranging study. Asian J Androl 2008. PMID 18097503
- Jin X, et al. Ganoderma lucidum (Reishi mushroom) for cancer treatment. Cochrane Database Syst Rev 2016. PMC6353236
- Xuanwu Hospital, Beijing. Efficacy and Safety of Lingzhi in Patients With Early Parkinson's Disease. ClinicalTrials.gov NCT00224263. NCT00224263
- Wanmuang H, et al. Fatal fulminant hepatitis associated with Ganoderma lucidum (Lingzhi) mushroom powder. J Med Assoc Thai 2007. PMID 17621752
- Yuen MF, et al. Hepatotoxicity due to a formulation of Ganoderma lucidum (lingzhi). J Hepatol 2004. PMID 15464254